Cutaneous leishmaniasis treated with miltefosine: A case series of 10 paediatric patients

Ayelet Ollech; Michal Solomon; Amir Horev; Shiran Reiss-Huss; Dan Ben-Amitai; Alex Zvulunov; Rivka Friedland; Vered Atar-Snir; Vered Pessach-Molcho; Aviv Barzilai; Shoshana Greenberger

doi:10.2340/00015555-3669

Cutaneous leishmaniasis treated with miltefosine: A case series of 10 paediatric patients

Ayelet Ollech, Michal Solomon, Amir Horev, Shiran Reiss-Huss, Dan Ben-Amitai, Alex Zvulunov, Rivka Friedland, Vered Atar-Snir, Vered Pessach-Molcho, Aviv Barzilai, Shoshana Greenberger

Medical School for International Health

Research output: Contribution to journal › Article › peer-review

8 Scopus citations

Abstract

Cutaneous leishmaniasis poses a therapeutic chal-lenge in the paediatric population. The aim of this study was to assess the efficacy and safety of miltefo-sine treatment for Old World cutaneous leishmaniasis in paediatric patients. A multicentre retrospective review of 10 children (≤ 18 years of age) with cutaneous leishmaniasis treated with miltefosine in Israel was performed. Mean ± standard deviation age at diagnosis was 9.1 ± 5.0 years. The Leishmania species diagnosed was L. tropica in 8 cases and Leishmania major in 2 cases. Mean ± standard deviation duration of treatment was 44.8 ± 20.6 days, with a mean follow-up period of 12.1 ± 17.1 months. Complete response was noted in 8 (80%) patients. Treatment failure was noted in 2 (20%) cases. Side-effects related to the medication were minimal. In conclusion, oral miltefosine may be an effective and safe treatment for Old World cutaneous leishmaniasis caused by Leishmania tropica or Leishmania major in children. However, further studies are warranted to draw a definite conclusion.

Original language	English
Article number	adv00322
Pages (from-to)	1-5
Number of pages	5
Journal	Acta Dermato-Venereologica
Volume	100
Issue number	18
DOIs	https://doi.org/10.2340/00015555-3669
State	Published - 1 Jan 2020

Keywords

Amphotericin B
Leishmania ma-jor
Leishmania tropica
Leishmaniasis
Miltefosine
Sodium stibogluconate

ASJC Scopus subject areas

Dermatology

Access to Document

10.2340/00015555-3669

Cite this

@article{cbfc03b1a1724e1cb70c9c018f03e155,

title = "Cutaneous leishmaniasis treated with miltefosine: A case series of 10 paediatric patients",

abstract = "Cutaneous leishmaniasis poses a therapeutic chal-lenge in the paediatric population. The aim of this study was to assess the efficacy and safety of miltefo-sine treatment for Old World cutaneous leishmaniasis in paediatric patients. A multicentre retrospective review of 10 children (≤ 18 years of age) with cutaneous leishmaniasis treated with miltefosine in Israel was performed. Mean ± standard deviation age at diagnosis was 9.1 ± 5.0 years. The Leishmania species diagnosed was L. tropica in 8 cases and Leishmania major in 2 cases. Mean ± standard deviation duration of treatment was 44.8 ± 20.6 days, with a mean follow-up period of 12.1 ± 17.1 months. Complete response was noted in 8 (80%) patients. Treatment failure was noted in 2 (20%) cases. Side-effects related to the medication were minimal. In conclusion, oral miltefosine may be an effective and safe treatment for Old World cutaneous leishmaniasis caused by Leishmania tropica or Leishmania major in children. However, further studies are warranted to draw a definite conclusion.",

keywords = "Amphotericin B, Leishmania ma-jor, Leishmania tropica, Leishmaniasis, Miltefosine, Sodium stibogluconate",

author = "Ayelet Ollech and Michal Solomon and Amir Horev and Shiran Reiss-Huss and Dan Ben-Amitai and Alex Zvulunov and Rivka Friedland and Vered Atar-Snir and Vered Pessach-Molcho and Aviv Barzilai and Shoshana Greenberger",

year = "2020",

month = jan,

day = "1",

doi = "10.2340/00015555-3669",

language = "English",

volume = "100",

pages = "1--5",

journal = "Acta Dermato-Venereologica",

issn = "0001-5555",

publisher = "Medical Journals Sweden AB",

number = "18",

}

TY - JOUR

T1 - Cutaneous leishmaniasis treated with miltefosine

T2 - A case series of 10 paediatric patients

AU - Ollech, Ayelet

AU - Solomon, Michal

AU - Horev, Amir

AU - Reiss-Huss, Shiran

AU - Ben-Amitai, Dan

AU - Zvulunov, Alex

AU - Friedland, Rivka

AU - Atar-Snir, Vered

AU - Pessach-Molcho, Vered

AU - Barzilai, Aviv

AU - Greenberger, Shoshana

PY - 2020/1/1

Y1 - 2020/1/1

N2 - Cutaneous leishmaniasis poses a therapeutic chal-lenge in the paediatric population. The aim of this study was to assess the efficacy and safety of miltefo-sine treatment for Old World cutaneous leishmaniasis in paediatric patients. A multicentre retrospective review of 10 children (≤ 18 years of age) with cutaneous leishmaniasis treated with miltefosine in Israel was performed. Mean ± standard deviation age at diagnosis was 9.1 ± 5.0 years. The Leishmania species diagnosed was L. tropica in 8 cases and Leishmania major in 2 cases. Mean ± standard deviation duration of treatment was 44.8 ± 20.6 days, with a mean follow-up period of 12.1 ± 17.1 months. Complete response was noted in 8 (80%) patients. Treatment failure was noted in 2 (20%) cases. Side-effects related to the medication were minimal. In conclusion, oral miltefosine may be an effective and safe treatment for Old World cutaneous leishmaniasis caused by Leishmania tropica or Leishmania major in children. However, further studies are warranted to draw a definite conclusion.

AB - Cutaneous leishmaniasis poses a therapeutic chal-lenge in the paediatric population. The aim of this study was to assess the efficacy and safety of miltefo-sine treatment for Old World cutaneous leishmaniasis in paediatric patients. A multicentre retrospective review of 10 children (≤ 18 years of age) with cutaneous leishmaniasis treated with miltefosine in Israel was performed. Mean ± standard deviation age at diagnosis was 9.1 ± 5.0 years. The Leishmania species diagnosed was L. tropica in 8 cases and Leishmania major in 2 cases. Mean ± standard deviation duration of treatment was 44.8 ± 20.6 days, with a mean follow-up period of 12.1 ± 17.1 months. Complete response was noted in 8 (80%) patients. Treatment failure was noted in 2 (20%) cases. Side-effects related to the medication were minimal. In conclusion, oral miltefosine may be an effective and safe treatment for Old World cutaneous leishmaniasis caused by Leishmania tropica or Leishmania major in children. However, further studies are warranted to draw a definite conclusion.

KW - Amphotericin B

KW - Leishmania ma-jor

KW - Leishmania tropica

KW - Leishmaniasis

KW - Miltefosine

KW - Sodium stibogluconate

UR - http://www.scopus.com/inward/record.url?scp=85096348759&partnerID=8YFLogxK

U2 - 10.2340/00015555-3669

DO - 10.2340/00015555-3669

M3 - Article

C2 - 33074340

AN - SCOPUS:85096348759

SN - 0001-5555

VL - 100

SP - 1

EP - 5

JO - Acta Dermato-Venereologica

JF - Acta Dermato-Venereologica

IS - 18

M1 - adv00322

ER -

Cutaneous leishmaniasis treated with miltefosine: A case series of 10 paediatric patients

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this